<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859115</url>
  </required_header>
  <id_info>
    <org_study_id>TENS_AVR</org_study_id>
    <nct_id>NCT03859115</nct_id>
  </id_info>
  <brief_title>Effects of TENS on Myocardial Protection in Patients Undergoing AVR</brief_title>
  <official_title>Effects of TENS on Myocardial Protection in Patients Undergoing AVR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing aortic valve replacement are randomized to receive TENS (transcutaneous
      electrical nerve stimulation) or sham stimulation at one arm for 30 min under various
      anesthetic conditions: no anesthesia (preanesthesia), sevoflurane or propofol anesthesia.
      Cardioprotective effects of TENS are compared through Langendorff rat heart perfusion system
      using plasma dialysate from patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing aortic valve replacement are randomized to one of six groups:
      preanesthesia-TENS (transcutaneous electrical nerve stimulation), preanesthesia-sham,
      sevoflurane-TENS, sevoflurane-sham, propofol-TENS, propofol-sham. Patients receive TENS or
      sham stimulation (without electrical pulse generation) at one arm for 30 min under no
      anesthesia (preanesthesia) or sevoflurane or propofol anesthesia.

      In all patients, blood samples are obtained before and after TENS or sham procedure to make
      plasma dialysate to perfuse rat hearts subjected to ischemia-reperfusion injury through
      Langendorff system.

      Cardioprotective effects are determined by comparing infarct sizes of rat hearts perfused
      with human plasma dialysate, which reflects cardioprotective effects of TENS in human
      subjects. By comparing infarct size differences, the myocardial protective effects of TENS in
      various anesthetic conditions can be determined in human subjects undergoing aortic valve
      replacement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">March 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size after TENS</measure>
    <time_frame>30 minutes</time_frame>
    <description>Infarct size of rat hearts perfused with dialysate after TENS compared with sham</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Myocardial Protection</condition>
  <arm_group>
    <arm_group_label>preanesthesia-TENS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preanesthesia-sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane-TENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane-sham</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol-TENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>propofol-sham</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TENS (transcutaneous electrical nerve stimulation)</intervention_name>
    <description>transcutaneous nerve stimulation with electrical pulse generation</description>
    <arm_group_label>preanesthesia-TENS</arm_group_label>
    <arm_group_label>propofol-TENS</arm_group_label>
    <arm_group_label>sevoflurane-TENS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sham intervention</intervention_name>
    <description>sham stimulation without electrical pulse generation</description>
    <arm_group_label>preanesthesia-sham</arm_group_label>
    <arm_group_label>propofol-sham</arm_group_label>
    <arm_group_label>sevoflurane-sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing aortic valve replacement

        Exclusion Criteria:

          -  co-medications: metformin, nitroglycerine, nicorandil, beta-blockers

          -  discomfort at TENS or loss of intact skin

          -  uncontrolled hypertension or diabetes mellitus

          -  severely impaired renal or hepatic function

          -  peripheral vasculopathy or neuropathy

          -  did not consent to participate

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunseok Jeon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunseok Jeon</last_name>
    <phone>82-2-2072-2465</phone>
    <email>jeonyunseok@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Youn Joung Cho</last_name>
    <phone>82-2-2072-3108</phone>
    <email>mingming7@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunseok Jeon, MD, PhD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>jeonyunseok@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yunseok Jeon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 25, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Yunseok Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>transcutaneous electrical nerve stimulation</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>propofol</keyword>
  <keyword>anesthesia</keyword>
  <keyword>myocardial protection</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

